Skip to main content

Taysha Gene Therapies, Inc.

TSHA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001806310

In the last 90 days, Taysha Gene Therapies, Inc. insiders filed 0 open-market purchases and 1 sale; 208 institutions reported holding it in 13F filings for Q2 2026, worth $2.03B in total; no superinvestor holds it.

Members of Congress who traded TSHA

No member of Congress has reported a trade in Taysha Gene Therapies, Inc. since 2020.

Source: U.S. House Clerk and Senate Office of Public Records (eFD). Amounts are the ranges filers report.